High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease
Sign Up to like & getrecommendations! Published in 2018 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01478-18
Abstract: Buruli ulcer (BU), caused by Mycobacterium ulcerans, is a neglected tropical skin and soft tissue infection that is associated with disability and social stigma. The mainstay of BU treatment is an 8-week course of rifampin… read more here.
Keywords: shorter oral; mycobacterium ulcerans; treatment; ulcerans disease ... See more keywords